Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2019 Feb 1;23(2):125-135. doi: 10.5588/ijtld.18.0866.

Health care gaps in the global burden of drug-resistant tuberculosis.

Author information

1
Center for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town.
2
Division of Medical Microbiology and the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
3
McGill International TB Centre, McGill University, Montreal, Quebec, Canada.
4
College of Liberal Arts and Sciences, Wayne State University, Detroit, Michigan.
5
Northwestern Pritzker School of Law, Chicago, Illinois, USA.
6
International Union Against TB and Lung Disease, Paris, France.

Abstract

The drug-resistant tuberculosis (DR-TB) cascade-from estimated or incident cases to numbers successfully treated or disease-free survival-has long been characterised by sharp declines at each step in the cascade. The losses along the cascade vary across different settings, and the reasons why some countries have a higher burden of DR-TB are complex and multifactorial; broadly, weak health systems, inadequate financing and poverty all impact differential access to DR-TB care. Within a human rights framework that mandates the right to health and the right to benefit from scientific progress, the aim of this review is to focus on describing inequities in access to DR-TB care at critical points in the cascade.

PMID:
30808447
DOI:
10.5588/ijtld.18.0866

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center